Litigation Details for CIPHER PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC.-FLORIDA (D.N.J. 2013)

CIPHER PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC.-FLORIDA (D.N.J. 2013)

Docket		Date Filed	2013-10-29
Court	District Court, D. New Jersey	Date Terminated	2015-10-30
Cause	35:271 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	None	Referred To	Ann Marie Donio
Parties	GALEPHAR PHARMACEUTICAL RESEARCH, INC.
Patents	7,435,427; 8,367,102
Attorneys	ELEONORE OFOSU-ANTWI
Link to Docket	External link to docket

Details for CIPHER PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC.-FLORIDA (D.N.J. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-10-29				External link to document

CIPHER PHARMACEUTICALS v. WATSON (1:13-cv-06502): Litigation Summary, Claims at Issue, and Case Status Analysis

Last updated: July 24, 2026

The case Cipher Pharmaceuticals, Inc. v. Watson Laboratories, Inc.-Florida, No. 1:13-cv-06502, is a US patent litigation matter in which Cipher sought to block or constrain Watson’s generic entry under the Hatch-Waxman framework. The core business impact is the extent to which the asserted patents prevented earlier FDA approval/launch, and whether the case resulted in a settlement that delayed marketing, narrowed claims, or licensed technology.

What is the litigation docket for CIPHER PHARMACEUTICALS INC v. WATSON LABORATORIES INC-FLORIDA 1:13-cv-06502?

Court, parties, and procedural posture

• Case caption: Cipher Pharmaceuticals, Inc. v. Watson Laboratories, Inc.-Florida
• Docket number: 1:13-cv-06502
• Forum: US District Court (federal case; district not specified in the prompt)
• Nature of suit: Hatch-Waxman / patent infringement (implied by the parties and case type)

What the docket typically contains in a Hatch-Waxman case

For this type of matter, the docket generally tracks:

• Patent list and asserted claims (from the Orange Book listing(s) for the reference drug)
• Allegations of infringement based on Watson’s ANDA (or related filing)
• Claim construction proceedings (Markman)
• Summary judgment motions (often on invalidity, non-infringement, or procedural defenses)
• Likely settlement events or final judgment dates

Which patents and claims were asserted in Cipher v. Watson (1:13-cv-06502)?

Asserted patent set and claim targets

A complete, accurate litigation analysis requires the specific asserted patent numbers and the claims Cipher alleged were infringed. That information is not provided in the request, and the docket number alone is insufficient to reconstruct the asserted claims reliably.

Claim themes that usually drive these disputes

In Hatch-Waxman disputes like Cipher v. Watson, the asserted patents commonly target:

• Formulation composition (e.g., particle engineering, excipient systems)
• Dosage form structure (e.g., release mechanisms)
• Method-of-use claims (therapeutic regimen dosing)
• Device and manufacturing methods (less common but seen in some portfolios)

Because the asserted patent set is not included here, the analysis cannot map infringement scope, claim construction outcomes, or the patent-by-patent strength.

What was the main legal theory in Cipher v. Watson: ANDA infringement, § 271(e)(2), or inducement?

Typical Hatch-Waxman infringement framing

The standard theory is:

• 35 USC § 271(e)(2): infringement based on the filing of an ANDA/ANDA-related acts reasonably expected to lead to infringement upon FDA approval.

Other theories that may appear depending on the case:

• § 271(a) direct infringement (post-approval conduct)
• § 271(b)/(c) inducement/contribution (training, labeling, sales practices)

Typical defenses in these cases

Common Watson defenses include:

• Non-infringement (no literal or equivalents match)
• Invalidity (anticipation, obviousness, lack of written description/enablement, indefiniteness)
• Statutory defenses (e.g., noninfringement under “no carve-out” or amendments affecting the scope)

Without claim-level detail and the court’s decisions, it is not possible to state which defenses succeeded or failed in this docket.

How did the court handle claim construction in Cipher v. Watson?

Markman issues that usually decide outcomes

Claim construction in formulation and method cases often turns on:

• Parameter limitations (particle size ranges, viscosity, dissolution targets)
• “Means-plus-function” provisions
• Release profile definitions (time to release, IR/UV test methods)
• Method-of-use wording tied to patient populations or dosing schedules

A litigation summary must identify:

• The claim terms construed
• The court’s constructions
• The effect of constructions on infringement/invalidity positions

Those specifics are not available in the prompt, so the analysis cannot be completed.

What was the settlement or outcome: did Cipher win an injunction or reach a compromise?

What outcomes matter commercially

In Hatch-Waxman cases, business outcomes typically break into:

• Final judgment of infringement leading to an injunction/delay
• Final judgment of invalidity or non-infringement, allowing entry
• Settlement agreement with an agreed launch date (“carve-out” or “design-around”)
• Consent judgments that narrow asserted claims

What this prompt does not provide

The prompt contains only the case identifier. It does not include:

• Judgment dates
• Settlement terms
• Whether an injunction issued
• Whether patents were found invalid, not infringed, or withdrawn

Accordingly, the case resolution cannot be stated accurately.

What Paragraph IV and ANDA timing risks existed for Watson in 1:13-cv-06502?

How Paragraph IV cases map to entry windows

If Watson filed a Paragraph IV certification, the litigation typically triggers:

• A 30-month stay of FDA approval (unless triggered exemptions apply)
• Potential earlier entry only if:
  • The court rules on infringement/validity within the statutory timeline, or
  • The parties settle, or
  • The stay expires by operation of law

Risk drivers that require docket facts

Risk is driven by:

• The number of asserted patents
• Whether any patents expire before the litigation timeline ends
• Whether “early decision” occurred
• Whether later patents were added or dropped

Because the asserted patent schedule and procedural milestones are not included, this section cannot be populated with accurate entry-window logic.

What is the Orange Book status of the reference drug in this dispute?

Needed elements for Orange Book mapping

To connect Orange Book status to litigation, one needs:

• The reference-listed drug (RLD) name
• Strength and dosage form
• Orange Book listing(s) tied to the asserted patents
• Patent expiration and listed exclusivities
• Whether patents were withdrawn or replaced

The prompt does not identify the RLD, the active ingredient, or the Orange Book listing(s), so Orange Book status cannot be stated.

Which company product and active ingredient were at issue in Cipher v. Watson?

Why the active ingredient matters

Cipher’s claims generally track the formulation or method-of-use of a specific drug. Without identifying:

• the branded product
• the active ingredient
• the dosage form (IR/ER, tablet/capsule, inhalation, etc.)

it is not possible to provide:

• infringement plausibility
• potential design-around space
• whether formulation/process patents were the target

No product identification is provided.

How strong was Cipher’s patent estate versus Watson’s likely generic design-around?

Patent strength analysis requires:

• asserted claims
• independent claim scope
• prosecution history (for estoppel or written description issues)
• the invalidity references cited in the record
• claim construction results

The prompt provides none of these. Any scoring would be speculative and would not meet the requirement for a complete and accurate response.

What other litigation or related cases affect the same patent portfolio?

Typical related-case patterns

Cipher and Watson portfolios may be involved in:

• Parallel district court cases in other venues
• PTAB challenges (inter partes review, post-grant review)
• Appeals to the Federal Circuit

No parallel proceedings are identified in the prompt, so this section cannot be completed.

Key Takeaways

• The case identifier 1:13-cv-06502 supports that this is a federal patent dispute between Cipher Pharmaceuticals and Watson Laboratories, Inc.-Florida.
• A litigation summary that covers asserted patents, claims, claim construction, judgment/settlement, and entry timing cannot be accurately produced from the docket number alone.
• No product, Orange Book listing, patent numbers, procedural milestones, or outcome details are provided in the prompt, so a complete and accurate litigation analysis cannot be delivered.

FAQs

1. What is the statutory basis for infringement in Paragraph IV ANDA cases like Cipher v. Watson?
2. How do claim construction outcomes typically affect infringement and invalidity in formulation patents?
3. What determines whether a 30-month stay of ANDA approval ends early in Hatch-Waxman litigation?
4. How do settlement terms usually structure generic launch dates in ANDA patent disputes?
5. What role do PTAB proceedings play in strengthening or weakening asserted patents during district court litigation?

References

1. (No sources cited; the prompt does not provide enough case or record data to cite specific filings, orders, patents, or docket entries.)